Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer cell

Showing results (1251-1260 of 3,827) with videos related to

Pageof 383
Sort By:
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Cancer Cell|July 2, 2019
RAC1<sup>P29S</sup> Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy ResistanceDaniël A Lionarons, David C Hancock, Sareena Rana, et al.
Cancer Cell|October 16, 2019
Venetoclax in Lymphoid Malignancies: New Insights, More to LearnRachel Thijssen, Andrew W Roberts
Cancer Cell|October 16, 2019
PRC2 Plays Red Light, Green Light with MHC-I and CD8<sup>+</sup> T CellsJohnathan R Whetstine
Cancer Cell|September 4, 2018
Ascorbic Acid in Cancer Treatment: Let the Phoenix FlyNiraj Shenoy, Edward Creagan, Thomas Witzig, et al.
Cancer Cell|September 12, 2018
Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma SubgroupsTenley C Archer, Tobias Ehrenberger, Filip Mundt, et al.
Cancer Cell|September 12, 2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASShunsuke Kitajima, Hajime Asahina, Ting Chen, et al.
Cancer Cell|September 12, 2018
Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML RecurrenceAllison L Boyd, Lili Aslostovar, Jennifer Reid, et al.
Cancer Cell|July 24, 2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationLingtao Jin, Jaemoo Chun, Chaoyun Pan, et al.
Cancer Cell|September 14, 2016
Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor EngagementRony Dahan, Jeffrey V Ravetch
Pageof 383

Showing results (1251-1260 of 3,827) with videos related to

Sort By:
Pageof 383
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Cancer Cell|July 2, 2019
RAC1<sup>P29S</sup> Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy ResistanceDaniël A Lionarons, David C Hancock, Sareena Rana, et al.
Cancer Cell|October 16, 2019
Venetoclax in Lymphoid Malignancies: New Insights, More to LearnRachel Thijssen, Andrew W Roberts
Cancer Cell|October 16, 2019
PRC2 Plays Red Light, Green Light with MHC-I and CD8<sup>+</sup> T CellsJohnathan R Whetstine
Cancer Cell|September 4, 2018
Ascorbic Acid in Cancer Treatment: Let the Phoenix FlyNiraj Shenoy, Edward Creagan, Thomas Witzig, et al.
Cancer Cell|September 12, 2018
Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma SubgroupsTenley C Archer, Tobias Ehrenberger, Filip Mundt, et al.
Cancer Cell|September 12, 2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASShunsuke Kitajima, Hajime Asahina, Ting Chen, et al.
Cancer Cell|September 12, 2018
Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML RecurrenceAllison L Boyd, Lili Aslostovar, Jennifer Reid, et al.
Cancer Cell|July 24, 2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationLingtao Jin, Jaemoo Chun, Chaoyun Pan, et al.
Cancer Cell|September 14, 2016
Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor EngagementRony Dahan, Jeffrey V Ravetch
Pageof 383